A micro-technology tool that can measure cells hundred times faster than current technologies has been developed by a research team at University of California, Los Angeles (UCLA) and Rutgers University.
The new tool could help in the discovery of medications for wide range of diseases related to abnormal use of force by cells.
The new device could make it easier and faster to test and evaluate new drugs for diseases associated with abnormal levels of cell strength, including hypertension, asthma and muscular dystrophy. It could also open new avenues for biological research into cell force. It is the first high-throughput tool that can measure the strength of thousands of individual cells at a time.
"Our new experimental platforms are capable of screening millions of molecules to identify the best drug candidates for the right patients," said Panettieri, Vice Chancellor, Clinical & Translational Science and director of the Rutgers Institute for Translational Medicine and Science. "The system leverages the state of the art bioengineering techniques and use of human cells derived from patients with chronic diseases that offer greater likelihood of predicting therapeutic responses."
"Our tool tracks how much force individual cells exert over time, and how they react when they are exposed to different compounds or drugs," said Dino Di Carlo, professor of bioengineering at the UCLA Henry Samueli School of Engineering and Applied Science and the project's principal investigator. "It's like a microscopic fitness test for cells with thousands of parallel stations."
Cells use physical force for essential biological functions, both as individual cells, for example in cell division or immune function, and as large groups of cells in tissue, for example, when muscles contract.
Disruptions in a cell's ability to control the levels of force they exert can lead to diseases or loss of important bodily functions. For example, asthma is caused by the smooth muscle cells that line the airways squeezing more than normal. And abnormally weak cell forces are associated with heart failure, muscular dystrophy and migraine headaches.
"Apart from demonstrating the feasibility of screening compounds for drug discovery, we also discovered that the conventional notion that increases in calcium levels within a cell are essential to control cell shortening or migration that is important in asthma or cancer metastasis was incorrect," Panettieri said. "Our observations using this novel platform offer a new paradigm regarding cell activation and approaches to screen molecules to target such processes."
The device is called fluorescently labeled elastomeric contractible surfaces, or FLECS. Its key component is a flexible rectangular plate with more than 100,000 uniformly spaced X-shaped micropatterns of proteins that are sticky so cells settle on and attach to them.
The X's embedded in the plate are elastic, so they shrink when the cells contract. The X's are made fluorescent with a molecular marker to enable imaging and quantification of how much the shapes shrink.
"Our platform can markedly improve the speed and fidelity of screening of millions of potential molecules in order to find new candidates that can rapidly progress through the approval process to become new drugs in asthma, cancer and heart disease," Panettieri said.
The X pattern the research team built into FLECS is just one option for how the plate can be configured. It can be adjusted to screen for a broad range of cell types by altering the patterns' shapes, stiffness and molecular composition.
To test the tool, the team analyzed drugs that make cells either contract or relax, using human smooth muscle cells that line airways in the body, in effect, simulating an asthma attack in the lab. The team compared the results of those tests to what was already known about how lung tissue reacts to the drugs and found that FLECS captured the same types of reactions, only more precisely because it could analyze the reactions in cell-by-cell detail.
The research team conducted additional testing to further demonstrate the device's versatility and effectiveness. For example, they tested the force of macrophages, cells in the immune system that rid the body of potentially harmful particles, bacteria and dead cells. They found that when a typical macrophage receives a signal that an infection is present, it can exert force approximately 200,000 times its own weight in water. But some macrophages were more than three times stronger than that.
The team also used FLECS to analyze cell force and then compared the results of that test to a current standard test, which judges cell force by analyzing the amount of calcium in the cells. They were surprised that the results of the calcium test did not correlate well with how much cells contracted. The finding suggests that the calcium test may be limited, because, unlike that test, FLECS looks at a level of detail down to an individual cell.
In collaboration with scientists from the Rutgers Institute for Translational Medicine and Science, the UCLA research team found that individuals cells from people who had died from severe asthma contract with more force, both generally and during an asthma attack, than they do in healthy people.
The complete research is published in the journal Nature Biomedical Engineering.